Amunix Pharmaceuticals is Biotechnology in United States that focus on peptide therapeutics business. Founded in 2006. They cover business area such as operator, novel biologic, protein, peptide therapeutic, ongoing collaboration, biopharma corporation, these delivery technology, therapeutic area, improved pharmaceutical technology, clinician, well efficacy, safety, dose frequency, extension.
2006
( 18 years old in 2024 )
Peptide Therapeutics
-
2 Tower Plaza
Suite 1100
South San Francisco, CA 94080
United States
Private
operatornovel biologicproteinpeptide therapeuticongoing collaborationbiopharma corporationthese delivery technologytherapeutic areaimproved pharmaceutical technologyclinicianwell efficacysafetydose frequencyextension
* We use standard office opening hours in near Amunix Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Amunix Pharmaceuticals is Biotechnology business from United States that founded in 2006 (18 years old in 2024), Amunix Pharmaceuticals business is focusing on Peptide Therapeutics.
Amunix Pharmaceuticals headquarter office and corporate office address is located in 2 Tower Plaza Suite 1100 South San Francisco, CA 94080 United States.
Amunix Pharmaceuticals was founded in United States.
In 2024, Amunix Pharmaceuticals is currently focus on peptide therapeutics sector.
Above is snippet of Google Trends for "peptide therapeutics" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Amunix Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
